Patents by Inventor Andreas Weith

Andreas Weith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to interleukin-like epithelial-mesenchymal transition inducer (ILEI)
    Patent number: 7745585
    Abstract: The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: June 29, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Zophel, Horst Johann Ahorn, Birgit Jung, Renate Konopitzky, Karl-Heinz Heider, Norbert Kraut, Peter Seither, Thomas Waerner, Hartmut Beug, Martin Jechlinger, Ido M. Tamir, Andreas Weith, Stefan Gruenert
  • Cytokine involved in epithelial-mesenchymal transition
    Publication number: 20070089176
    Abstract: The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.
    Type: Application
    Filed: September 2, 2004
    Publication date: April 19, 2007
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Andreas Zoephel, Horst Ahorn, Birgit Jung, Renate Konopitzky, Karl-Heinz Heider, Norbert Kraut, Peter Seither, Thomas Waerner, Hartmut Beug, Martin Jechlinger, Ido Tamir, Andreas Weith, Stefan Gruenert
  • Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
    Publication number: 20040253630
    Abstract: The present invention relates to substances which modulate receptors involved in inflammatory processes and whose modulated functions positively influence inflammatory diseases.
    Type: Application
    Filed: June 22, 2004
    Publication date: December 16, 2004
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Birgit Jung, Norbert Kraut, Stefan Mueller, Barbara Kistler, Peter Seither, Karsten Quast, Andreas Weith
  • Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
    Patent number: 6773895
    Abstract: The present invention relates to substances which modulate receptors involved in inflammatory processes and whose modulated functions positively influence inflammatory diseases.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: August 10, 2004
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Birgit Jung, Norbert Kraut, Stefan Mueller, Barbara Kistler, Peter Seither, Karsten Quast, Andreas Weith
  • Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
    Publication number: 20020119494
    Abstract: The present invention relates to substances which modulate receptors involved in inflammatory processes and whose modulated functions positively influence inflammatory diseases.
    Type: Application
    Filed: August 31, 2001
    Publication date: August 29, 2002
    Inventors: Birgit Jung, Norbert Kraut, Stefan Mueller, Barbara Kistler, Peter Seither, Karsten Quast, Andreas Weith
  • Neuroblastoma-associated regulator gene
    Patent number: 5683878
    Abstract: Disclosed is a gene situated in the region of the neuroblastoma consensus deletion 1p36.2-p36.1 which codes for a helix-loop-helix protein with the designation HEIR-1. The loss of this gene is significantly correlated with allelic tumor deletions in neuroblastomas and expression of this correlates inversely both N-myc overexpression in tumors and with N-myc expression in normal development. The cDNA and antibodies coding for HEIR-1 are used for the diagnosis of pathological conditions associated with aberration in the region of the neuroblastoma consensus deletion.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 4, 1997
    Assignees: Boehringer Ingelheim International GmbH, Genentech, Inc.
    Inventors: Wilfried Ellmeier, Andreas Weith
  • Neuroblastoma-associated regulator gene
    Patent number: 5654188
    Abstract: Described is a gene situated in the region of the neuroblastoma consensus deletion 1p36.2-p36.1 and which codes for a helix-loop-helix protein with the designation HEIR-1. The gene is affected significantly by allelic tumor deletions in neuroblastomas and correlates inversely both N-myc overexpression in tumors and with N-myc expression in normal development. The cDNA and antibodies coding for HEIR-1 are used for the diagnosis of pathological conditions associated with aberration in the region of the neuroblastoma consensus deletion.
    Type: Grant
    Filed: June 23, 1994
    Date of Patent: August 5, 1997
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Wilfried Ellmeier, Andreas Weith